Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

All Set For EU Approval: First Biosimilar Humalog And Three More Rituximabs From Celltrion

Executive Summary

The European Medicines Agency has given the thumbs-up to Insulin lispro Sanofi, the first biosimilar version of Lilly’s diabetes drug Humalog. It has also green-lighted three more biosimilar rituximab products from Celltrion, which already has EU approval for one version of the originator product, Roche’s MabThera.

Advertisement

Related Content

'Affordable' Russian Rituximab Biosimilar On Course In India
Sandoz Files Biosimilar Humira & Remicade In EU; 13 Products Now Under Evaluation By CHMP
Decade-Old Advanced Therapy Set For EU Approval
EU Approval Recommendations: Strong Showing From Orphans & Biosimilars
Sanofi’s Franchise Defense Sees Biosimilar Insulin Lispro Under EU Review

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel